EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische Studie

A Phase 1a/1b Dose Escalation/Expansion Study of the Anti-PD-1 Monoclonal Antibody Nofazinlimab in Chinese Patients with Solid Tumors or Lymphoma

Jifang Gong, Ye Guo, Yanqiao Zhang, Yi Ba, Tong Chen, Wei Li, Caicun Zhou, Mengzhao Wang, Haiyan Yang, Yuhong Zhou, Qiqing Cai, Ziping Wang und 10 weitere

Targeted Oncology · 2024

DOI: 10.1007/s11523-024-01091-8 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Targeted Oncology, 2024. Verfasst von Jifang Gong und 21 weiteren Autor:innen. Beteiligte Einrichtung: Peking University Cancer Hospital & Institute, Beijing, China. Hauptthemen laut MEDLINE: Lymphoma, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: CStone Pharmaceuticals Co. Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) antibodies has demonstrated efficacy in multiple tumor types. Nofazinlimab is a humanized rat antibody targeting PD-1. A first-in-human study of nofazinlimab conducted in Australia found no dose-limiting toxicities (DLTs) and the maximum tolerated dose (MTD) was not reached in the range of 1-10 mg/kg. OBJECTIVE: We evaluated nofazinlimab for multiple advanced malignancies in Chinese patients. PATIENTS AND METHODS: This was a phase 1a/1b, open-label, multicenter, dose-escalation/expansion trial. In phase 1a, patients received an abbreviated dose escalation of nofazinlimab at 60 mg and 200 mg every 3 weeks (Q3W) to determine DLTs and the recommended phase 2 dose (RP2D). In phase 1b, patients received the RP2D (monotherapy/combination) in six arms by tumor type; DLTs were evaluated for nofazinlimab plus lenvatinib in the unresectable hepatocellular carcinoma (uHCC) arm. Safety (continuously monitored in patients who received nofazinlimab) and efficacy (patients with measurable baseline disease) were assessed. RESULTS: Overall, 107 patients were eligible and received nofazinlimab. In phase 1a, no DLTs were observed; the RP2D was 200mg Q3W. In phase 1b, no DLTs were observed with nofazinlimab plus lenvatinib. The safety profile was consistent with that observed in the first-in-human study (NCT03475251). In phase 1b, 21/88 (23.9%) patients achieved confirmed objective responses, 26 (29.5%) had stable disease, and 9/20 (45.0%) patients with uHCC achieved confirmed objective responses to nofazinlimab plus lenvatinib. CONCLUSIONS: Nofazinlimab was well tolerated in Chinese patients. Preliminary efficacy was encouraging, particularly for nofazinlimab plus lenvatinib in uHCC, which is being studied in an ongoing phase 3 trial. CLINICAL TRIAL REGISTRATION: NCT03809767; registered 18 January 2019.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LymphomaNeoplasmsHumansMaleFemaleMiddle AgedAgedAdultChinaProgrammed Cell Death 1 ReceptorAntibodies, Monoclonal, HumanizedMaximum Tolerated DoseEast Asian People

Substanzen

Programmed Cell Death 1 ReceptorAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Peking University Cancer Hospital & Institute, Beijing, China.
  • Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
  • Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.
  • Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
  • Huashan Hospital, Fudan University, Shanghai, China.
  • The First Hospital of Jilin University, Changchun, Jilin, China.

ORCID-Profile: Lin Shen

Förderung

  • CStone Pharmaceuticals Co. Ltd.

Zitieren

APA

Gong, J., Guo, Y., Zhang, Y., Ba, Y., Chen, T., Li, W., Zhou, C., Wang, M., Yang, H., Zhou, Y., Cai, Q., Wang, Z., Huang, G., Zhang, W., Su, R., Cai, Z., Yue, Z., Dou, J., Li, P., …, & Shen, L. (2024). A Phase 1a/1b Dose Escalation/Expansion Study of the Anti-PD-1 Monoclonal Antibody Nofazinlimab in Chinese Patients with Solid Tumors or Lymphoma. Targeted Oncology. https://doi.org/10.1007/s11523-024-01091-8

Vancouver

Gong J, Guo Y, Zhang Y, Ba Y, Chen T, Li W, et al. A Phase 1a/1b Dose Escalation/Expansion Study of the Anti-PD-1 Monoclonal Antibody Nofazinlimab in Chinese Patients with Solid Tumors or Lymphoma. Targeted Oncology. 2024. doi:10.1007/s11523-024-01091-8

BibTeX
@article{Gong2024,
  author = {Gong, Jifang and Guo, Ye and Zhang, Yanqiao and Ba, Yi and Chen, Tong and Li, Wei and Zhou, Caicun and Wang, Mengzhao and Yang, Haiyan and Zhou, Yuhong and Cai, Qiqing and Wang, Ziping and Huang, Gang and Zhang, Wei and Su, Rila and Cai, Zhongheng and Yue, Zenglian and Dou, Jinzhou and Li, Peiqi and Wu, Rachel and Tse, Archie N and Shen, Lin},
  title = {A Phase 1a/1b Dose Escalation/Expansion Study of the Anti-PD-1 Monoclonal Antibody Nofazinlimab in Chinese Patients with Solid Tumors or Lymphoma},
  journal = {Targeted Oncology},
  year = {2024},
  doi = {10.1007/s11523-024-01091-8}
}
Kostenlos starten →